Physician profile
James Reardon
NPI 1891889978
$1,184.60
in general payments reported to CMS, 2019-2025
6 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $786 · 2021: $30.00 · 2022: $126 · 2023: $65.74 · 2024: $177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $242.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Steelhead Surgical INC | $758.00 | 2019 | |
| Heron Therapeutics, INC. | $215.16 | 2021-2024 | Zynrelef |
| Zimmer Biomet Holdings, INC. | $96.14 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $63.32 | 2024 | Onivyde, Somatuline Depot |
| Smith+Nephew, INC. | $27.67 | 2019 | |
| Depuy Synthes Sales INC. | $24.31 | 2024 | Na |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Reardon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.